Dexmedetomidine versus standard of care for the management of severe agitation in patients at end of life.
Phase 2
Recruiting
- Conditions
- AgitationNeurological - Other neurological disorders
- Registration Number
- ACTRN12621001499875
- Lead Sponsor
- Dr Lana Ferguson
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
•Palliative diagnosis with a prognosis of 6 months or less;
•Patient has agitation requiring pharmacological management (RASS-PAL greater than or equal to +2);
•18 years and over.
Exclusion Criteria
•Patients with known AV block in the absence of functioning pacemaker;
•Bradycardia (baseline heart rate less than 55 beats per minute);
•Patients with end-stage heart failure with documented ejection fraction <20%;
•Hypotension (systolic blood pressure < 90mmHg);
•Patients with a chronic mental health history who are taking long-term antipsychotic medication.
•Non-English speaking
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The mean time to achieving a RASS-PAL score </= 0.<br>Compare time infusion was started with time RASS-PAL score </= 0 achieved; this will be achieved by reviewing medical records, electronic prescribing programme (Medi-map) and data recorded on case report forms.[Study duration of 72 hours from initiation of treatment]
- Secondary Outcome Measures
Name Time Method